Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Alar Doses First Patient in ALA-3000 Study for Treatment-Resistant Depression
Details : ALA-3000, developed by Alar Pharmaceuticals, is the first formulation of ketamine lasting over one week in the blood following single dose and is being developed for Treatment-Resistant Depression.
Product Name : ALA-3000
Product Type : Controlled Substance
Upfront Cash : Inapplicable
May 14, 2025
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Buprenorphine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The Buprenorphine release from the ALA-1000 single injection lasts over 12 weeks with effective concentrations, showing low initial burst without dose dumping effect and good safety and tolerability, including local skin irritation and injection pain sev...
Product Name : ALA-1000
Product Type : Controlled Substance
Upfront Cash : Inapplicable
September 03, 2021
Lead Product(s) : Buprenorphine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable